Table 2. Univariate analysis of disease-free survival, overall survival, and distant metastasis-free survival in patients with breast cancer.
| Disease-free survival | Overall survival | Distant metastasis-free survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | HR | (95% CI) | P value | HR | (95% CI) | P value | HR | (95% CI) | P value | |||
| Age | ||||||||||||
| <50 | 1.00 | 1.00 | 1.00 | |||||||||
| ≥50 | 0.72 | 0.54 | 0.96 | 0.024 | 1.08 | 0.81 | 1.43 | 0.599 | 0.75 | 0.55 | 1.01 | 0.058 |
| Tumour size | ||||||||||||
| 0–2 | 1.00 | 1.00 | 1.00 | |||||||||
| 2.1–5 | 1.63 | 1.21 | 2.20 | 0.001 | 1.63 | 1.19 | 2.24 | 0.002 | 1.71 | 1.24 | 2.36 | 0.001 |
| ≥5.1 | 2.00 | 1.17 | 3.42 | 0.011 | 2.60 | 1.58 | 4.28 | <0.001 | 2.34 | 1.36 | 4.03 | 0.002 |
| LN metastasis | ||||||||||||
| Negative | 1.00 | 1.00 | 1.00 | |||||||||
| Positive | 2.60 | 1.95 | 3.46 | <0.001 | 2.10 | 1.57 | 2.80 | <0.001 | 2.94 | 2.16 | 4.01 | <0.001 |
| Pn | ||||||||||||
| 0 | 1.00 | 1.00 | 1.00 | |||||||||
| 1 | 1.78 | 1.25 | 2.52 | 0.001 | 1.40 | 0.97 | 2.03 | 0.071 | 1.92 | 1.31 | 2.81 | 0.001 |
| 2 | 2.92 | 1.96 | 4.33 | <0.001 | 2.17 | 1.43 | 3.29 | <0.001 | 3.39 | 2.24 | 5.14 | <0.001 |
| 3 | 4.95 | 3.41 | 7.18 | <0.001 | 4.03 | 2.78 | 5.84 | <0.001 | 5.77 | 3.90 | 8.55 | <0.001 |
| Pathologic stage | ||||||||||||
| I | 1.00 | 1.00 | 1.00 | |||||||||
| II | 1.88 | 1.24 | 2.87 | 0.003 | 1.77 | 1.15 | 2.72 | 0.010 | 2.19 | 1.36 | 3.54 | 0.001 |
| III | 4.41 | 2.88 | 6.76 | <0.001 | 3.91 | 2.53 | 6.04 | <0.001 | 5.60 | 3.47 | 9.05 | <0.001 |
| Histologic grade | ||||||||||||
| 1 | 1.00 | 1.00 | 1.00 | |||||||||
| 2 | 1.77 | 0.98 | 3.20 | 0.059 | 1.72 | 0.93 | 3.18 | 0.087 | 1.86 | 0.95 | 3.65 | 0.069 |
| 3 | 2.35 | 1.32 | 4.19 | 0.004 | 2.44 | 1.34 | 4.44 | 0.003 | 2.85 | 1.49 | 5.47 | 0.002 |
| Nuclear grade | ||||||||||||
| 1 | 1.00 | 1.00 | 1.00 | |||||||||
| 2 | 1.56 | 0.88 | 2.79 | 0.130 | 1.19 | 0.69 | 2.06 | 0.529 | 1.44 | 0.79 | 2.64 | 0.233 |
| 3 | 2.06 | 1.15 | 3.68 | 0.015 | 1.48 | 0.85 | 2.57 | 0.164 | 2.00 | 1.09 | 3.66 | 0.026 |
| Chemotherapy | ||||||||||||
| No | 1.00 | 1.00 | 1.00 | |||||||||
| Yes | 1.88 | 1.10 | 3.24 | 0.022 | 0.75 | 0.50 | 1.12 | 0.163 | 2.46 | 1.30 | 4.65 | 0.006 |
| Radiotherapy | ||||||||||||
| No | 1.00 | 1.00 | 1.00 | |||||||||
| Yes | 1.73 | 1.28 | 2.34 | <0.001 | 1.33 | 0.99 | 1.80 | 0.062 | 1.88 | 1.36 | 2.62 | <0.001 |
| Hormone therapy | ||||||||||||
| No | 1.00 | 1.00 | 1.00 | |||||||||
| Yes | 1.12 | 0.84 | 1.49 | 0.440 | 0.90 | 0.68 | 1.21 | 0.498 | 1.09 | 0.80 | 1.47 | 0.589 |
| EIC | ||||||||||||
| Negative | 1.00 | 1.00 | 1.00 | |||||||||
| Positive | 0.71 | 0.49 | 1.02 | 0.065 | 0.69 | 0.47 | 1.02 | 0.062 | 0.68 | 0.46 | 1.00 | 0.053 |
| p53 | ||||||||||||
| Negative | 1.00 | 1.00 | 1.00 | |||||||||
| Positive | 1.00 | 0.74 | 1.34 | 0.981 | 0.87 | 0.64 | 1.18 | 0.373 | 1.05 | 0.77 | 1.44 | 0.749 |
| ER | ||||||||||||
| Negative | 1.00 | 1.00 | 1.00 | |||||||||
| Positive | 1.12 | 0.84 | 1.48 | 0.436 | 0.90 | 0.68 | 1.20 | 0.484 | 1.09 | 0.81 | 1.47 | 0.559 |
| PR | ||||||||||||
| Negative | 1.00 | 1.00 | 1.00 | |||||||||
| Positive | 1.05 | 0.80 | 1.38 | 0.714 | 0.89 | 0.67 | 1.17 | 0.397 | 0.93 | 0.70 | 1.24 | 0.614 |
| HER2 | ||||||||||||
| Negative | 1.00 | 1.00 | 1.00 | |||||||||
| Positive | 1.37 | 1.03 | 1.84 | 0.033 | 1.34 | 0.99 | 1.81 | 0.058 | 1.26 | 0.92 | 1.72 | 0.149 |
| Subtype | ||||||||||||
| Luminal A | 1.00 | 1.00 | 1.00 | |||||||||
| Luminal B | 1.26 | 0.86 | 1.85 | 0.242 | 1.39 | 0.93 | 2.09 | 0.106 | 1.18 | 0.78 | 1.78 | 0.447 |
| HER2 | 1.27 | 0.85 | 1.88 | 0.238 | 1.31 | 0.86 | 2.00 | 0.203 | 1.19 | 0.78 | 1.83 | 0.416 |
| TNBC | 0.76 | 0.52 | 1.09 | 0.134 | 1.09 | 0.76 | 1.56 | 0.637 | 0.82 | 0.56 | 1.19 | 0.292 |
| CD24 | ||||||||||||
| Low | 1.00 | 1.00 | 1.00 | |||||||||
| High | 1.46 | 1.10 | 1.94 | 0.009 | 1.57 | 1.18 | 2.10 | 0.002 | 1.36 | 1.00 | 1.84 | 0.047 |
Abbreviations: LN, lymph node; EIC, extensive intraductal component; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; HR, hazard ratio; CI, confidence interval. HRs with P values of less than 0.05 are marked in bold.